The final draft guidance from the National Institute for Health and Care Excellence (NICE) specifically applies to patients who are inadequately controlled with high dose inhaled corticosteroids plus another maintenance therapy. Eligible patients will have had three or more exacerbations in the previous year, or are having maintenance oral corticosteroids.
The decision was supported by positive data from the PATHFINDER clinical trial programme, including one phase 3 study which demonstrated a 56% reduction in the annualised asthma exacerbation rate in these patients receiving Tezspire compared to placebo…
